We bring you our round-up of the latest legal and commercial issues for life sciences businesses.
With just five weeks to go until the end of the transition period, we cover some important issues relating to Brexit for businesses in the sector: where we are in the process and how to mitigate the key risks, the likely implications of a “no deal” Brexit, and the impact of Brexit on supplementary protection certificates.
We also give an overview of an important contractual mechanism often used in the life sciences industry when acquiring and disposing of assets in order to streamline and develop project workstreams.
A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.
Charlotte Tillett
Gustaf Duhs